Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis

NCT02548351 is registered in ClinicalTrials.gov with Intercept Pharmaceuticals as lead sponsor.

NCT NCT02548351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02548351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Lead sponsor
Intercept Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
September 22, 2015
Completion date
September 15, 2023
Enrollment
2,477 (actual)
Sites
346

Conditions

As the registry lists them; a condition with its own page is linked.

non alcoholic steatohepatitis (nash)